Safety, pharmacokinetics and pharmacodynamics of TAK‐418, a novel inhibitor of the epigenetic modulator lysine‐specific demethylase 1A

AIMS: Dysregulation of histone methylation epigenetic marks may result in intellectual and developmental disability, as seen in Kabuki syndrome. Animal data suggest that increasing histone methylation by inhibiting lysine‐specific demethylase 1A (LSD1) may improve cognitive outcomes in a model of Ka...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Wei, Arkilo, Dimitrios, Khudyakov, Polyna, Hazel, Jim, Gupta, Saurabh, Quinton, Maria S., Lin, Jie, Hartman, Deborah S., Bednar, Martin M., Rosen, Laura, Wendland, Jens R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290503/
https://www.ncbi.nlm.nih.gov/pubmed/33990969
http://dx.doi.org/10.1111/bcp.14912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290503/
https://www.ncbi.nlm.nih.gov/pubmed/33990969
http://dx.doi.org/10.1111/bcp.14912

Ejemplares similares